Compare medications

Max 4 meds. Sources include DailyMed labels; verify against official labeling. Last reviewed shown per row. On small screens the table defaults to a compact view—use “Show all columns” to view everything (scroll horizontally). Visit individual drug pages for narratives, printable summaries, and therapeutic drug monitoring notes.

Add up to 4 medications

0/4 selected

Browse catalog

Oral Antipsychotics

Second Generation Antipsychotics (SGAs)

First Generation Antipsychotics (FGAs)

Long‑acting Injectable Antipsychotics (LAIs)

Mood Stabilizers

Adjunctive Medications

Ketamine & rapid-acting antidepressants (2)

Benzodiazepines (12)

Sleep & circadian agents (14)

ADHD & wakefulness agents (14)

Substance use treatment & harm reduction (11)

Metabolic & weight management (4)

Other adjunctive medications (17)

Compact view hides Indications, MOA, PK, TDM, Monitoring, and Reviewed.

Medication	Indications (label)	Dosing highlights	MOA	PK	TDM	Risk flags	Monitoring	LAI options	Last reviewed
nefazodoneAdjunctive therapyBrands: Serzone View labelExact	Depression (label). View labelExact	Label initiation is typically 200 mg/day divided BID, with titration toward 300–600 mg/day as tolerated; dose increases are commonly spaced at one-week intervals in labeling (label).	Serotonin antagonist and reuptake inhibitor (SARI-like): inhibits serotonin/norepinephrine uptake with 5-HT2 and α1 antagonism; notable for rare but life-threatening hepatic failure and strong CYP3A4 inhibition.	CYP3A4 \| Single-dose range 2–4 h	No	Sedation	Baseline assessment for liver disease and review of hepatic warning signs/symptoms at follow-up (label/clinical). Medication reconciliation focused on CYP3A4 interactions, including sedative-hypnotics and common non-psychiatric drugs (label/clinical). Orthostatic vitals and functional safety (falls risk), especially in older adults and polypharmacy (clinical). Suicidality and mood switching surveillance early in treatment and after dose changes (label/clinical).	No	2025-12-30
trazodoneAdjunctive therapyBrands: DESYREL, OLEPTRO View labelExact	Major depressive disorder (label); commonly used off label for insomnia. View labelExact	Insomnia (off label): start 25–50 mg at bedtime; typical 50–150 mg nightly based on tolerability; reassess frequently and avoid open-ended dose escalation.	Serotonin antagonist and reuptake inhibitor (SARI); 5-HT2 antagonism with weak SERT inhibition plus H1/α1 effects.	CYP3A4 \| Single-dose mean 7 h; Single-dose range 5–13 h	No	Sedation QTc	Monitor orthostatic symptoms and falls risk during initiation and after dose increases, especially in older adults or those on antihypertensives. Reassess mood and suicidality during antidepressant initiation and titration; ensure the dose matches the target (sleep vs depression). Review QT-risk co-medications and consider ECG/electrolytes when risk factors stack. If used primarily for insomnia, document a stop plan and reassess regularly rather than continuing indefinitely.	No	2025-12-28
venlafaxineAdjunctive therapyBrands: Effexor XR View labelExact	Major depressive disorder; generalized anxiety disorder; social anxiety disorder; panic disorder. View labelExact	Initiate XR 37.5 mg once daily with food for 4–7 days, then 75 mg/day; increase by 75 mg increments at ≥7-day intervals up to 225 mg/day (300 mg off-label).	Serotonin-norepinephrine reuptake inhibitor (SNRI).	CYP2D6, CYP3A4 (minor), UGT \| Single-dose mean 5 h; Single-dose range 4–6 h; Steady-state mean 11 h; Steady-state range 9–13 h	No	—	Blood pressure and heart rate at baseline and after titration, with extra attention at higher doses. Discontinuation symptoms during missed doses or tapering; plan refill timing and taper steps proactively. Sodium in older adults or diuretic users if symptoms suggest hyponatremia (confusion, fatigue, falls). Mood elevation or agitation in bipolar-spectrum illness; coordinate prevention plans via the bipolar disorder hub. Medication reconciliation to avoid serotonergic combinations and to plan MAOI washouts when regimens change.	No	2025-10-05
mirtazapineAdjunctive therapyBrands: Remeron View labelExact	Major depressive disorder. View labelExact	Typical adult initiation: 15 mg at bedtime; increase to 30 mg after 1–2 weeks based on response; usual maintenance 15–45 mg nightly.	Central presynaptic alpha-2 antagonist; enhances noradrenergic and serotonergic transmission (NaSSA).	CYP1A2, CYP2D6, CYP3A4 \| Single-dose mean 30 h; Single-dose range 20–40 h; Steady-state mean 37 h	No	Weight Sedation	Weight and appetite changes, plus fasting lipids and glucose at baseline and periodically, given weight gain and dyslipidemia risk. Daytime sedation and falls risk, especially in older adults and when other sedatives are co-prescribed. Infection symptoms (fever, sore throat) given rare neutropenia; prompt evaluation is appropriate when symptoms arise. Mood elevation or agitation in bipolar-spectrum illness; coordinate prevention plans via the bipolar disorder hub.	No	2025-10-05

Compare tool FAQ

How many medications can I compare at once?

You can line up to four medications at a time. Use the search box to add or remove drugs, then press “Compare” to refresh the table.

Where does the comparison data come from?

Most fields are generated from our curated facts + per-drug profiles. DailyMed label links come from source metadata, and LAI options come from our LAI catalog.

Can I save or share a comparison?

Yes. The Share button copies a link you can send to teammates, and we store your most recent selection so you can restore it next time you visit.